Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/JU.0000000000004418 | DOI Listing |
JAMA Netw Open
January 2025
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel.
Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.
View Article and Find Full Text PDFMol Oncol
January 2025
Urologic Oncology Research Group, Cancer Research Program, Research Institute of the McGill University Health Center, Montreal, Canada.
Patient stratification remains a challenge for optimal treatment of prostate cancer (PCa). This clinical heterogeneity implies intra-tumoural heterogeneity, with different prostate epithelial cell subtypes not all targeted by current treatments. We reported that such cell subtypes are traceable in liquid biopsies through representative transcripts.
View Article and Find Full Text PDFUrol Oncol
January 2025
Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Objectives: To evaluate the concordance between the intraoperative visual assessment of the tumor bed for completeness of resection following partial nephrectomy and the permanent section analysis of biopsies taken from the tumor bed.
Methods: Patients undergoing partial nephrectomy at 2 university hospitals were prospectively enrolled. R.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!